Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Blood Science (Baltimore, Md.)|April 11, 2022
Current status and hurdles for CAR-T cell immune therapyRuocong Zhao, Yuanbin Cui, Shanglin Li, et al.Biophysics Reports|March 22, 2024
CAR designs for solid tumors: overcoming hurdles and paving the way for effective immunotherapyYuanbin Cui, Mintao Luo, Chuanyuan Gu, et al.Molecular Therapy. Oncology|April 20, 2026
Chimeric antigen receptor T cell targeting CD44E variant in HCC holds therapeutic potentialRui Liao, Cecilia Ka Wing Chan, Yuanbin Cui, et al.Molecular Therapy. Oncology|June 17, 2024
Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinomaLinfu Zhou, Yao Li, Diwei Zheng, et al.Frontiers in Immunology|July 30, 2021
Human Hyaluronidase PH20 Potentiates the Antitumor Activities of Mesothelin-Specific CAR-T Cells Against Gastric CancerRuocong Zhao, Yuanbin Cui, Yongfang Zheng, et al.Cellular Oncology (Dordrecht, Netherlands)|April 14, 2025
HBO1 determines epithelial-mesenchymal transition and promotes immunotherapy resistance in ovarian cancer cellsCong Zhang, Jinmin Zhu, Huaisong Lin, et al.Cell Reports|November 23, 2017
Kdm2b Regulates Somatic Reprogramming through Variant PRC1 Complex-Dependent FunctionZhiwei Zhou, Xuejie Yang, Jiangping He, et al.Nature Communications|October 13, 2022
Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axisLe Qin, Yuanbin Cui, Tingjie Yuan, et al.Molecular Therapy Oncolytics|July 5, 2022
DAP10 integration in CAR-T cells enhances the killing of heterogeneous tumors by harnessing endogenous NKG2DShanglin Li, Ruocong Zhao, Diwei Zheng, et al.Cell Reports|July 12, 2023
T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activityYuanbin Cui, Tingjie Yuan, Ying Wang, et al.Pageof 2